AGL 38.02 Increased By ▲ 0.08 (0.21%)
AIRLINK 197.36 Increased By ▲ 3.45 (1.78%)
BOP 9.54 Increased By ▲ 0.22 (2.36%)
CNERGY 5.91 Increased By ▲ 0.07 (1.2%)
DCL 8.82 Increased By ▲ 0.14 (1.61%)
DFML 35.74 Decreased By ▼ -0.72 (-1.97%)
DGKC 96.86 Increased By ▲ 4.32 (4.67%)
FCCL 35.25 Increased By ▲ 1.28 (3.77%)
FFBL 88.94 Increased By ▲ 6.64 (8.07%)
FFL 13.17 Increased By ▲ 0.42 (3.29%)
HUBC 127.55 Increased By ▲ 6.94 (5.75%)
HUMNL 13.50 Decreased By ▼ -0.10 (-0.74%)
KEL 5.32 Increased By ▲ 0.10 (1.92%)
KOSM 7.00 Increased By ▲ 0.48 (7.36%)
MLCF 44.70 Increased By ▲ 2.59 (6.15%)
NBP 61.42 Increased By ▲ 1.61 (2.69%)
OGDC 214.67 Increased By ▲ 3.50 (1.66%)
PAEL 38.79 Increased By ▲ 1.21 (3.22%)
PIBTL 8.25 Increased By ▲ 0.18 (2.23%)
PPL 193.08 Increased By ▲ 2.76 (1.45%)
PRL 38.66 Increased By ▲ 0.49 (1.28%)
PTC 25.80 Increased By ▲ 2.35 (10.02%)
SEARL 103.60 Increased By ▲ 5.66 (5.78%)
TELE 8.30 Increased By ▲ 0.08 (0.97%)
TOMCL 35.00 Decreased By ▼ -0.03 (-0.09%)
TPLP 13.30 Decreased By ▼ -0.25 (-1.85%)
TREET 22.16 Decreased By ▼ -0.57 (-2.51%)
TRG 55.59 Increased By ▲ 2.72 (5.14%)
UNITY 32.97 Increased By ▲ 0.01 (0.03%)
WTL 1.60 Increased By ▲ 0.08 (5.26%)
BR100 11,727 Increased By 342.7 (3.01%)
BR30 36,377 Increased By 1165.1 (3.31%)
KSE100 109,513 Increased By 3238.2 (3.05%)
KSE30 34,513 Increased By 1160.1 (3.48%)
Editorials

Researchers create new type of gene-editing technology to fight diseases

In order fight diseases more effectively, Chinese researchers claim to have developed a totally new type of gene-ed
Published July 20, 2019 Updated July 23, 2019

In order fight diseases more effectively, Chinese researchers claim to have developed a totally new type of gene-editing technology that will serve as a better alternative to the CRISPR one.

Researchers from China’s Peking University have created a new gene-editing technology dubbed ‘LEAPER’. They believe that the new technology shows a more promising result as an alternative to CRISPR gene-editing tech for fighting human diseases.

LEAPER, which stands for ‘leveraging endogenous ADAR for programmable editing of RNA’, works in a similar fashion to the CRISPR-Cas13 that targets RNA molecules as opposed to the DNA ones like it’s done in CRISPR-Cas9, explained Futurism.

Scientists close to HIV cure in humans after treating mice through gene-editing

The CRISPR-Cas13 is dependent on both a guide RNA and the Cas13 enzyme in order to make the edits to its RNA. The LEAPER, in comparison, requires just one component called ‘arRNA’, which in turn makes the system ‘more easily deliverable and less likely to result in unwanted cellular immune responses’, the team told Chinese new outlet Caixin.

Since the technology does not change the DNA directly and rather makes use of native proteins, it is unlikely to cause any heritable changes, while also being precise and safe at the same time, researcher Zhou Zhuo told The Global Times.

In the tests of cells taken from people with the genetic disorder Hurler syndrome, the new LEAPER system was able to correct ‘sufficient amounts’ of the cells’ mutated RNA. Zhuo said that there are obvious prospects in using this technology is disease treatment and can act as a good potential alternative.

Moreover, the research is still in its early stages, with the team now moving on to animal tests. Hence, it will take time for LEAPER to entirely replace CRISPR as the paramount gene-editing technology.

Copyright Business Recorder, 2019

Comments

Comments are closed.